Skip to main content
In 2024, 77 pts referred to Rheum for possible PMR were ultimately Dx w/ B19 viral infx. 96% had arthralgia & 7% ha

Dr. John Cush RheumNow

8 months 3 weeks ago
In 2024, 77 pts referred to Rheum for possible PMR were ultimately Dx w/ B19 viral infx. 96% had arthralgia & 7% had PMR-like features (5/5 w/ BL shoulder/neck. prolonged AM stiff, fever & Hi CRP/ESR - none had hip pain. 4/5 were male, w/ mean age of 55 yrs. None were RF/CCP+ https://t.co/AiK2K9whBH
A matched cohort study shows that HLA-B*58:01 and HLA-A*34:02 are strongly associated with allopurinol-induced severe cutaneous adverse reactions (SCARs), these alleles were absent in more than one-third of those affected, suggesting these are strong but incomplete indicators of SCAR risk. 
New ACR 2025 Guidelines for Non-Renal Lupus
  • MedPage Today
Written by Lisa Sammaritano, MD, of the Hospital for Special Surgery in New York City, and a committee of nearly 50 other experts, the new guideline also stipulates that corticosteroids are OK for gaining symptom control in newly diagnosed patients and when flares erupt, but the duration should be kept as short as possible.
There is a growing burden of #OA among middle-aged adults, rising by 123.7%, from 11.8 million in 1990 to 26.4 million i

Dr. John Cush RheumNow

8 months 3 weeks ago
There is a growing burden of #OA among middle-aged adults, rising by 123.7%, from 11.8 million in 1990 to 26.4 million in 2021. 56.5% of incident cases & 38% of prevalent cases occur in middle-aged group (70% higher than the elderly (>60 years) population). Highest in hi-income. https://t.co/JVpZ96qe0E
20-40% of Autoimmune hepatitis (AIH) is associated with other autoimmune diseases - lead by autoimmune thyroiditis, type

Dr. John Cush RheumNow

8 months 3 weeks ago
20-40% of Autoimmune hepatitis (AIH) is associated with other autoimmune diseases - lead by autoimmune thyroiditis, type 1 DM, ulcerative colitis, Crohn disease, & celiac (but less so for RA, PBC, SLE, Sjögren syndrome, vitiligo). AIH Dx Abs include ANA, ASMA, LKM1. https://t.co/I3ZPHiRgqZ
Sjogren’s disease: two drugs with positive trials Sjogren’s disease: two drugs with positive trials

After several

Dr. John Cush RheumNow

8 months 3 weeks ago
Sjogren’s disease: two drugs with positive trials Sjogren’s disease: two drugs with positive trials After several failures of therapies in Phase 3 trials of Sjogren’s disease (SjD) over many years, all hope is not lost! At #ACR25, not one but two drugs presented their efficacy https://t.co/kTTdZnVUtj
RETREAT study was a 12 wk RCT of Tai Chi in 178 knee OA pts Rx w/ online OA info vs same plus free web based tai chi vi

Dr. John Cush RheumNow

8 months 3 weeks ago
RETREAT study was a 12 wk RCT of Tai Chi in 178 knee OA pts Rx w/ online OA info vs same plus free web based tai chi video program. Tai Chi group had signif improved knee pain (−2.7 v -1.2); (−12 v −6.9) & achieved a minimal pain & function (73% v 47%); and Its free! https://t.co/WLzQ9YHrcu
Off the Shelf: CAR-T

Dr. Akhil Sood reports on abstract 0663 (iPSC-Derived Off-the-Shelf anti-CD19 CAR T cells Deliver

Dr. John Cush RheumNow

8 months 3 weeks ago
Off the Shelf: CAR-T Dr. Akhil Sood reports on abstract 0663 (iPSC-Derived Off-the-Shelf anti-CD19 CAR T cells Deliver Improved Clinical Outcomes in Lupus with Reduced or No Conditioning Chemotherapy) presented at#ACR25. https://t.co/mj4b5cCInC https://t.co/s34atFCMlx
AI in Fellow Recruitment: A New Dawn in Medical Education?

Drs. Mrinalini Dey and Bharat Kumar abstract 2174 (Using Na

Dr. John Cush RheumNow

8 months 3 weeks ago
AI in Fellow Recruitment: A New Dawn in Medical Education? Drs. Mrinalini Dey and Bharat Kumar abstract 2174 (Using Natural Language Processing to Identify Character Strengths in Rheumatology Fellowship Candidate Applications: A Feasibility Study) presented at #ACR25. https://t.co/gGx4zZlfAm
Beyond the Breakthrough: Equity and Access in CAR-T Cell Therapy for RA

At #ACR25, abstract 1039, "Global Cost-Effecti

Dr. John Cush RheumNow

8 months 3 weeks ago
Beyond the Breakthrough: Equity and Access in CAR-T Cell Therapy for RA At #ACR25, abstract 1039, "Global Cost-Effectiveness and Equity in CAR-T Cell Therapy for Rheumatoid Arthritis," highlights the critical economic and ethical dimensions of CAR-T cell therapy in autoimmune https://t.co/Rci0dL7THj
“It is not the strongest of the species that survive, nor the most intelligent, but the one most responsive to change.

Dr. John Cush RheumNow

8 months 3 weeks ago
“It is not the strongest of the species that survive, nor the most intelligent, but the one most responsive to change." – Charles Darwin
Are we putting the CAR-T before the horse?

CAR T-cells have been a revolutionary development in rheumatology. We have

Dr. John Cush RheumNow

8 months 3 weeks ago
Are we putting the CAR-T before the horse? CAR T-cells have been a revolutionary development in rheumatology. We have seen a population of patients with severe refractory autoimmune conditions almost overnight presented with the prospect of not just improvement, but of a cure. https://t.co/gF9FXjAZ7F
B Cell Depletion: Check the Lymph Node

Dr. Akhil Sood reports on abstract 2695 (B-cell depletion and lymphoid follicle

Dr. John Cush RheumNow

8 months 3 weeks ago
B Cell Depletion: Check the Lymph Node Dr. Akhil Sood reports on abstract 2695 (B-cell depletion and lymphoid follicle disruption upon different B-cell depleting agents) presented at #ACR25. https://t.co/bvZMGWNzfe https://t.co/dB6iQlgoYx
900,000 vs 9
It takes about 900,000 minutes to become a board-certified dermatologist. At that point, you might be very

Dr. John Cush RheumNow

8 months 3 weeks ago
900,000 vs 9 It takes about 900,000 minutes to become a board-certified dermatologist. At that point, you might be very skilled and well-informed. It takes less than nine minutes to make your patient feel seen, understood and reassured. If you skip the 9 minutes, you wasted the https://t.co/o7BaWjS4HB
IL-23 Blockade Goes Oral

A new player is entering the IL-23 arena — and it’s a tablet! Icotrokinra (ICO), a first-

Dr. John Cush RheumNow

8 months 3 weeks ago
IL-23 Blockade Goes Oral A new player is entering the IL-23 arena — and it’s a tablet! Icotrokinra (ICO), a first-in-class peptide that binds and blocks the interleukin-23 receptor (IL-23R), is showing encouraging efficacy and safety across a range of psoriasis (PSO) and https://t.co/7awBk16ZrQ
×